Novavax Shares Pop Another 50% Following Sanofi Deal
By Ben Glickman
Shares of Novavax continued their ascent on Monday, adding to gains from last week after the company announced a licensing deal with Sanofi.
The stock was up 50% to $13.31 in afternoon trading, reaching its highest intraday level since December 2022. Shares roughly doubled on Friday following the news, and are now up more than threefold in the last three months.
Novavax said Friday morning that it had agreed to a licensing deal with Sanofi to commercialize its Covid-19 vaccine worldwide. The company said it would receive up to $1.4 billion under the deal, inclusive of milestone payments.
Sanofi will have the sole license to use the Covid-19 vaccine in combination with its flu vaccine.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 13, 2024 14:14 ET (18:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
With a 4% Dividend Yield and Significant Growth Potential, This Stock Is a Buy
-
10 Stocks the Best Fund Managers Have Been Buying
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?